NeuroInflammatory Aspects in Rheumatology

How to Obtain AMA PRA Category 1 Credit(s)™

  1. Watch the CME Webcast.
  2. Take the CME posttest.
  3. Login to your account.
  4. Complete the registration / evaluation form.
  5. Print your personalized CME certificate.

Rheumatology
Online CME
Survey

 

 

 

   
 

Decision-Making in an Era of Efficacious Biologics:
PML Complicating Rheumatic and Autoimmune
Diseases and Their Therapies

Print this Content
 
 

This activity has expired. Please visit our Online CME Index for more CME offerings.

Technical Requirements
(will appear in new window)

 

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of XXX AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.

Target Audience

This activity will be directed to rheumatologists, neurologists and other specialists managing patients with rheumatic and other autoimmune and inflammatory diseases of the central and peripheral nervous system who are being treated with immunosuppressive and/or biologic therapies.

Description

The Cleveland Clinic has developed this webcast series entitled Neuroinflammatory Aspects in Rheumatology which discusses the CNS and PNS aspects of rheumatic diseases. This series covers four topics NP-SLE, Vasculitis of the CNS, Vasculitis of the PNS and Infectious complications of the CNS in immunosuppressed patients.

Objectives

At the conclusion of this activity, the participant will be able to:

  1. Discuss the varied clinical courses undergone by MS patients as a background for decision making.
  2. Describe the therapeutic mechanism of natalizumab and its relation to the induced susceptibility to PML.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology

Faculty

Richard Ransohoff, MD

Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:

Leonard Calabrese, DO

Consulting, Teaching and Speaking Genentech
 
  Teaching and Speaking Abbott; Amgen; Wyeth
 

Consulting Roche
 
 
Richard Ransohoff, MD
  Consulting
Biogen Idec
Estimated Time of Completion XXX

The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:

Genentech and Biogen Idec.

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.

CME Disclaimer